Compare PECO & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PECO | INDV |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.7B |
| IPO Year | 2010 | 2014 |
| Metric | PECO | INDV |
|---|---|---|
| Price | $37.23 | $36.06 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $39.71 | N/A |
| AVG Volume (30 Days) | 773.4K | ★ 1.4M |
| Earning Date | 04-23-2026 | 06-08-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | 74.51 | ★ 8100.00 |
| EPS | 0.56 | ★ 1.67 |
| Revenue | $726,594,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $3.81 | N/A |
| P/E Ratio | $66.29 | ★ $21.57 |
| Revenue Growth | ★ 9.86 | 4.29 |
| 52 Week Low | $32.98 | $22.56 |
| 52 Week High | $44.38 | $42.81 |
| Indicator | PECO | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 52.03 |
| Support Level | $36.50 | $35.49 |
| Resistance Level | $40.80 | $36.62 |
| Average True Range (ATR) | 0.61 | 0.89 |
| MACD | -0.03 | 0.32 |
| Stochastic Oscillator | 27.48 | 74.68 |
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).